leisure time -WSS

leisure time

author：entertainment 2025-08-19 15:02:09 - browse：93

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Addressing health care workers' trauma can help fight burnout

focus

WSS

10 states plan to sue EPA over standards for residential wood

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

Biogen joins immunology wave with $1.15 billion acquisition of HI

Listen: More tumult at BIO & coercive care for sickle cell patients

Elon Musk announces 'temporary limits' for reading Twitter posts

FDA poised to publish guidelines for clinical trial diversity

hotspot

leisure time

hotspot

Continuity nursing helped my family in our darkest PICU moments

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

State Dept. review finds Biden bears some blame for Afghanistan failures

1 dead, 9 hurt in July 4th fireworks explosion

Continuity nursing helped my family in our darkest PICU moments

1 dead, 9 hurt in July 4th fireworks explosion

Malaria cases in Florida and Texas: Here’s what you need to know

4 dead, 2 in stable condition in Philadelphia shooting: Police

hotspot

Biogen joins immunology wave with $1.15 billion acquisition of HI

Digital health: a case of mistaken identity

US judge blocks portions of new Florida elections law

10 states plan to sue EPA over standards for residential wood

July 4th fireworks can be stressful for dogs. These 6 tips can keep them calm and safe

Scrutiny of post

focus

entertainment

focus

hotspot